Clinical Trial Update: TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on TTFields combined with pulsed bevacizumab for recurrent glioblastoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Glioblastoma Multiforme
• Malignant Glioma

Drugs mentioned

• TTFields (Tumor Treating Fields)
• pulsed bevacizumab (bevacizumab)

Snippet

Sponsor: University of Florida | Conditions: Glioblastoma Multiforme, Glioblastoma | Phase 2 | Status: TERMINATED | Results posted: 2022-06-23